


Dear collaborators, partners, and members of the MoLBi community,


There is much to share and celebrate at MoLBi this September. With 376 patients now enrolled, our community continues to grow, bringing new opportunities to learn from each patient's contribution. This month also saw a special milestone in connecting our research with patient care, alongside opportunities to showcase MoLBi at Monash and internationally. Back in the laboratory, we are expanding our capacity to support the next stage of our research. These achievements reflect the collective efforts of our patients, families, clinicians, researchers and supporters. Thank you for helping us bring MoLBi's vision to life.

A milestone for Tonie and MoLBi

This month, Tonie Dalton became the first MoLBi patient with glioblastoma to receive the off-the-shelf PTX102 mRNA cancer vaccine. For our team, this is an important step towards the purpose that brought MoLBi together: connecting the study of patients' tumours with opportunities to explore new treatments. We are deeply grateful to the Monash Health research and governance teams, the Human Research Ethics Committee (HREC), the Clinical Trial Centre nursing staff, the early phase team and pharmacy for their expertise, dedication and collective efforts in making this possible. *"Anh, Janet, Tonie and Nathan – in Monash Health Clinical Trial Centre"*



This is a treatment milestone, and it is too early to know the outcome. We send Tonie and her family our warmest wishes and thank them for their trust and involvement in the MoLBi community.



Sharing our work at Monash

On Monday 7 September, MoLBi featured in the Homegrown Innovation Showcase during Research and Innovation Week 2026, hosted by Professor Euan Wallace. It was an opportunity to share how our clinicians and researchers are working together to connect discoveries in the laboratory with questions that matter in patient care.


Connecting with colleagues internationally

September also took MoLBi to the Hebei–Australia Expert Exchange Forum on Biopharmaceutical and Medical Technology. The forum provided an opportunity to introduce our platform to an international audience and explore shared interests in translational cancer research.

We were pleased to re-connect with John Xie Zhengzheng, Director Pharmacist at Beijing Shijitan Hospital, Capital Medical University pictured with Gwo Yaw Ho, who visited our research facility last year. We look forward to continuing these conversations and exploring opportunities for collaboration.



Read the Monash University story: [MoLBi showcased on the international stage](#)



More room for our CAM program

Back in the laboratory, we have invested in a 400-egg incubator to expand our chick chorioallantoic membrane, or CAM, model program. This will give the team more capacity to develop this part of MoLBi's research platform and support future projects. As the program grows, this investment will help us accommodate more research projects and strengthen the link between tumour collection and laboratory investigation. *"Yoseph with the new incubator"*

Visit our revamped MoLBi website

We have also revamped our MoLBi website! Please visit to learn more about the platform, meet our team and collaborators, and catch up on our latest news and newsletters. We hope it will be a useful way to stay connected with the program as it grows. Please share it with colleagues and others who may be interested in our work.

Visit the [MoLBi website](#).

Thank you for being part of MoLBi

Each of these steps depends on people working together. Thank you to our patients and families, consumer partners, clinical and laboratory teams, collaborators and supporters. Your contributions help us build a program that keeps patients at the centre of the research.

With best wishes,



Dr Gwo Yaw Ho
Founder and Chair, Monash Live-Biobanking



Professor Justin Moore
Director of Neurosurgery, Monash Health